SOLARA

Solara Active Pharma Sciences Share Price

₹491.10 +23.1 (4.94%)

22 Feb, 2025 21:22

SIP TrendupStart SIP in SOLARA

Start SIP

Performance

  • Low
  • ₹465
  • High
  • ₹491
  • 52 Week Low
  • ₹327
  • 52 Week High
  • ₹883
  • Open Price₹480
  • Previous Close₹468
  • Volume185,641

Investment Returns

  • Over 1 Month -27.14%
  • Over 3 Month -35.5%
  • Over 6 Month -29.52%
  • Over 1 Year + 11.56%
SIP Lightning

Smart Investing Starts Here Start SIP with Solara Active Pharma Sciences for Steady Growth!

Invest Now

Solara Active Pharma Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -7.8
  • PEG Ratio
  • -0.4
  • Market Cap Cr
  • 1,977
  • P/B Ratio
  • 1.8
  • Average True Range
  • 30.42
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -40.84
  • RSI
  • 38
  • MFI
  • 48.64

Solara Active Pharma Sciences Financials

Solara Active Pharma Sciences Technicals

EMA & SMA

Current Price
₹491.10
+ 23.1 (4.94%)
pointer
  • stock-down_img
  • Bullish Moving Average 2
  • stock-up_img
  • Bearish Moving Average 14
  • 20 Day
  • ₹521.86
  • 50 Day
  • ₹592.53
  • 100 Day
  • ₹636.77
  • 200 Day
  • ₹619.05

Resistance and Support

482.5 Pivot Speed
  • R3 526.40
  • R2 508.90
  • R1 500.00
  • S1 473.60
  • S2 456.10
  • S3 447.20

What's your outlook on Solara Active Pharma Sciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Solara Active Pharma Sciences Ltd. is a leading pharmaceutical company in India, specializing in the production of active pharmaceutical ingredients (APIs) and intermediates. The company focuses on innovation, quality, and sustainability, catering to various therapeutic segments in the global market.

Solara Active Pharma Scis has an operating revenue of Rs. 1,310.18 Cr. on a trailing 12-month basis. An annual revenue de-growth of -12% needs improvement, Pre-tax margin of -38% needs improvement, ROE of -60% is poor and needs improvement. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Solara Active Pharma Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-24 Quarterly Results
2024-10-21 Quarterly Results
2024-07-22 Quarterly Results
2024-05-29 Audited Results
2024-05-09 To consider Fund Raising

Solara Active Pharma Sciences F&O

Solara Active Pharma Sciences Shareholding Pattern

37.23%
1.28%
14.67%
0.03%
21.93%
24.86%

About Solara Active Pharma Sciences

  • NSE Symbol
  • SOLARA
  • BSE Symbol
  • 541540
  • Managing Director & CEO
  • Mr. Poorvank Purohit
  • ISIN
  • INE624Z01016

Similar Stocks to Solara Active Pharma Sciences

Solara Active Pharma Sciences FAQs

Solara Active Pharma Sciences share price is ₹491 As on 22 February, 2025 | 21:08

The Market Cap of Solara Active Pharma Sciences is ₹1976.9 Cr As on 22 February, 2025 | 21:08

The P/E ratio of Solara Active Pharma Sciences is -7.8 As on 22 February, 2025 | 21:08

The PB ratio of Solara Active Pharma Sciences is 1.8 As on 22 February, 2025 | 21:08

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23